

1 Title page

2 **Genetic liability to sedentary behavior increases the risk of cardiovascular**  
3 **disease incidence: Evidence from the FinnGen cohort with 293,250**  
4 **individuals**

5 Joensuu L.<sup>1\*</sup>, Koivunen K.<sup>1</sup>, Tynkkynen N.<sup>1</sup>, Palviainen T.<sup>2</sup>, Kaprio J.<sup>2</sup>, FinnGen, Klevjer  
6 M.<sup>3,4</sup>, Øvretveit K.<sup>5</sup>, Wisløff U.<sup>3</sup>, Bye A.<sup>3,4</sup>, Ekelund U.<sup>6,7</sup>, Sillanpää, E.<sup>1,8</sup>.

7 <sup>1</sup>Gerontology Research Center, Faculty of Sport and Health Sciences, University of  
8 Jyväskylä, Jyväskylä, FINLAND; <sup>2</sup>Institute for Molecular Medicine Finland, HiLIFE,  
9 University of Helsinki, Helsinki, FINLAND; <sup>3</sup>Cardiac Exercise Research Group, Department  
10 of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian  
11 University of Science and Technology, Trondheim, NORWAY; <sup>4</sup>Clinic of Cardiology, St.  
12 Olav's Hospital, Trondheim, NORWAY; <sup>5</sup>HUNT Center for Molecular and Clinical  
13 Epidemiology, Department of Public Health and Nursing, Norwegian University of Science  
14 and Technology, Trondheim, NORWAY; <sup>6</sup>Norwegian School of Sport Sciences, Oslo,  
15 NORWAY; <sup>7</sup>Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo,  
16 NORWAY; <sup>8</sup>Wellbeing Services County of Central Finland, Jyväskylä, FINLAND

17 Correspondence to:

18 \*Laura Joensuu, [laura.p.joensuu@jyu.fi](mailto:laura.p.joensuu@jyu.fi), +358504363466, Faculty of Sport and Health  
19 Sciences, University of Jyväskylä PO Box 35, FI-40014 Jyväskylä, Finland

20 Running title: Genetic sedentarism and cardiovascular disease

21 Total word count: 7811

## 22 **Abstract**

### 23 **Background**

24 It is unclear how the genetics of sedentary behavior are associated with incident  
25 cardiovascular disease (CVD). We investigated the associations between genetic liability to  
26 sedentary behavior, sedentariness, and four main CVD outcomes: any CVD, hypertensive  
27 diseases, ischemic heart diseases, and cerebrovascular diseases.

### 28 **Methods**

29 Leisure screen time was used as a proxy for sedentary behavior. We developed a polygenic  
30 score for leisure screen time (PGS LST) based on over 890,000 genetic variants. We tested  
31 the validity of this score against self-reported LST in the older Finnish Twin Cohort (FTC,  
32 N=2,689, mean age of 60.5±3.7 years, 54.7% women) using linear regression. We examined  
33 the associations between PGS LST and register-based records of CVDs using survival  
34 models among FinnGen participants (N=293,250–333,012, 67.0±13.0 years at follow-up,  
35 52.3% women). We replicated analyses in an independent cohort (Trøndelag Health Study  
36 [HUNT], N=35,289, 64.0±13.1 years, 51.6% women) and explored if the associations persist  
37 following adjustments for socioeconomic status, body mass index, and smoking or are  
38 mediated via reduced physical activity.

### 39 **Results**

40 In the FTC, each standard deviation increase in PGS LST was associated with greater self-  
41 reported LST (hours/day) ( $\beta = 0.09$ , 95% CI: 0.05–0.14). In FinnGen, each standard  
42 deviation increase in PGS LST was associated with a higher risk of incident CVD (hazard  
43 ratio: 1.05, [1.05–1.06]) (168,770 cases over 17,101,133 person-years). The magnitudes of  
44 association for three most common CVDs were 1.09 (1.08–1.09), 1.06 (1.05–1.07), and 1.05  
45 (1.04–1.06) for hypertensive diseases, ischemic heart diseases, and cerebrovascular diseases,  
46 respectively. Those in the top decile of PGS LST had 21%, 35%, 26%, and 19% higher risk

47 of any CVD, hypertensive diseases, ischemic heart diseases, and cerebrovascular diseases,  
48 respectively, than those in the bottom decile. Associations replicated in HUNT and remained  
49 independent of covariates except for cerebrovascular diseases. Besides direct effects, reduced  
50 physical activity served as a potential mediating pathway for the associations.

## 51 **Conclusions**

52 A higher genetic liability to sedentary behavior is associated with a greater risk of developing  
53 CVDs, although effect sizes with current PGS remain small. Our findings suggest that genetic  
54 liability to sedentary behavior is an underrecognized driver of common CVDs.

## 55 **Clinical perspective**

56 What is new?

- 57 • It is not known whether a genetic liability to sedentary behavior is a mutual  
58 underlying factor for both sedentary behavior and incident cardiovascular disease at  
59 the population level.
- 60 • We observed that a higher polygenic score for leisure screen time was associated with  
61 more self-reported leisure screen time and a higher risk of common cardiovascular  
62 diseases.

63 What are the clinical implications?

- 64 • This study provides novel insights into the relationship between genetic  
65 predisposition to sedentary behavior and the development of cardiovascular diseases,  
66 shedding light on a previously underexplored aspect of disease etiology.
- 67 • These results may motivate health professionals to encourage sedentary persons to  
68 undertake at least some physical activity.

## 69 **Introduction**

70 Cardiovascular diseases (CVDs) are the leading cause of disease burden and death  
71 worldwide.<sup>1</sup> Sedentary behavior is any waking behavior in a sitting, reclining, or lying  
72 posture and characterized by an energy expenditure of less than or equal to 1.5 metabolic  
73 equivalents.<sup>2</sup> Adults spend up to 60% of their awake time sedentary.<sup>3</sup> The prevalence of  
74 sedentary behaviors has remained stable or even increased during the last 20 years.<sup>4</sup>  
75 Sedentary behaviors are systematically associated with increased risk of CVD incidence and  
76 related mortality in prospective observational cohort studies.<sup>5,6</sup>

77 Interestingly, energy-saving sedentary behavior has been suggested to be a trait selected by  
78 evolution to ensure reproduction and survival.<sup>7</sup> Thus, genetics may be an important driver of  
79 sedentary behavior, as supported by previous evidence from twin and candidate gene  
80 studies.<sup>8</sup> However, the potential effects of this genetic liability on morbidity are unclear.  
81 From an evolutionary perspective, it is plausible that genetic predisposition to sedentary  
82 behavior increases the risk of common non-communicable diseases.<sup>9,10</sup> It has been suggested  
83 that the rapid environmental changes in societies, particularly in Western countries, may have  
84 led to an “evolutionary mismatch”.<sup>9</sup> In this scenario, the previously advantageous alleles, e.g.  
85 the genetic liability for sedentary behavior, may cause morbidity in the current post-industrial  
86 environment.<sup>11</sup> Furthermore, as life expectancy has increased, the deleterious effects of  
87 underlying genetics may become more apparent.<sup>10</sup> The theory of antagonistic pleiotropy  
88 suggests that some genes that have favored survival during reproductive ages in the past may  
89 currently limit lifespan and increase morbidity.<sup>12</sup> Underlying genetics may therefore be an  
90 important confounding factor in the commonly observed associations between sedentary  
91 behavior and incident CVD.

92 Polygenic scores (PGSs) summarize the genome-wide information between single-nucleotide

93 polymorphisms (SNPs) and a phenotype into a single variable that quantifies a person's  
94 genetic liability for a given trait.<sup>13</sup> In this study, we assess whether a higher genetic liability  
95 for sedentary behavior is associated with an increased risk of incident CVD at the population  
96 level. Leisure screen time (LST) is a commonly reported voluntary mode of sedentary  
97 behavior and thus serves as a proxy for this trait.<sup>6</sup> We hypothesized that higher genetic  
98 liability for LST, as measured by a polygenic score (PGS LST), is associated with an  
99 increased risk of developing a CVD.

## 100 **Methods**

101 This study consists of four phases. First, we constructed a PGS for LST. Second, we assessed  
102 the validity of this score against self-reported LST in the older Finnish Twin Cohort (FTC).  
103 Third, we assessed the associations between the PGS LST and incident CVD in the FinnGen  
104 cohort (~10% of the Finnish population). Finally, we replicated the analyses in an  
105 independent cohort (The Trøndelag Health Study [the HUNT study]). The study design and  
106 cohorts are shown in Figure 1. Additionally, we conducted exploratory analyses to estimate  
107 the potential explanations for the observed associations.

### 108 *Study cohorts*

109 *Base data for PGS LST.* We used the publicly available genome-wide association study  
110 (GWAS) summary statistics previously published by Wang et al. (2022) as the base data for  
111 PGS LST calculation. The data included 526,725 genotyped individuals from 24 different  
112 cohorts with European ancestry (mean age of  $49.5 \pm 7.6$  years). For more information  
113 regarding the base data, please see Table S1.

114 *Validation cohort.* The FTC is a prospective population-based cohort study that began in  
115 1975 and has provided a 50-year follow-up resource for genetic epidemiology. The study

116 details have been described elsewhere, but briefly, all same-sex twins born before 1958 and  
117 residing in Finland were invited to participate in the study.<sup>14</sup> The majority of the invitees  
118 accepted (response rate of 84.4%, N = 31,145). In this study, we used a genotyped sub-  
119 sample of the FTC who completed a questionnaire on their sedentary behavior in 2011 (N =  
120 2,689, mean age of  $60.5 \pm 3.7$  years, 54.7% women) (Table S2).

121 *Main cohort.* FinnGen is a public–private partnership research project linking genotype and  
122 digital health record data from Finnish health registries using unique national personal  
123 identification numbers. The FinnGen data release 11 comprises 520,210 biobank participants  
124 (<https://www.finngen.fi/en>).<sup>15</sup> The biobanks include regional, hospital-based biobanks (Auria  
125 Biobank, Biobank of Central Finland, Biobank of Eastern Finland, Borealis Biobank,  
126 Helsinki Biobank, Tampere Biobank), the Blood Service Biobank, the Terveystalo Biobank,  
127 and the Finnish Institute for Health and Welfare (THL) Biobank, which includes phenotypic  
128 and genetic information from the following studies: Botnia, Corogene, FinHealth 2017,  
129 FinIPF, FINRISK 1992–2012, GeneRisk, Health 2000, Health 2011, Kuusamo, Migraine,  
130 Super, T1D, and Finnish Twin Cohort. In our study, we excluded participants under the age  
131 of 40 years at the end of the follow-up. This was done to focus on a more homogenous adult  
132 population and CVDs, which develop over time. This process resulted in a sample of 293,250  
133 participants for incidence of any CVD. We used the same criteria to obtain samples for the  
134 three most prevalent CVDs in the FinnGen, with 322,890 participants for hypertensive  
135 diseases, 333,012 for ischemic heart diseases, and 332,730 for cerebrovascular diseases. The  
136 larger sample sizes for the three most common CVDs result from their later onset in life  
137 compared to all potential CVD diagnoses.

138 *Replication and exploratory cohort.* The HUNT study is conducted in the Trøndelag region  
139 of Norway. It commenced in 1984, inviting all residents 20 years old and above in the former

140 county of Nord-Trøndelag, now Trøndelag, to participate. To date, a total of four surveys  
141 have been completed: HUNT1 (1984–1986, N = 77,202, 89.4% participation rate), HUNT2  
142 (1995–1997, N = 65,228, 69.5% participation rate), HUNT3 (2006–2008, N = 50,800, 54.1%  
143 participation rate), and HUNT4 (2017–2019, N = 56,04, 54.0% participation rate).<sup>16</sup> The  
144 study data include laboratory measurements, questionnaires, interviews, and clinical  
145 examinations performed by trained personnel. More information about HUNT is available on  
146 the project's website ([ntnu.edu/hunt](https://ntnu.edu/hunt)). In this study, we used a subsample of individuals from  
147 HUNT2 and HUNT3 with available genotype and health record data (N = 35,289).

#### 148 ***Ethical considerations***

149 The base data for PGS LST were published in the National Human Genome Research  
150 Institute-European Bioinformatics Institute GWAS Catalog. The catalog follows the General  
151 Data Protection Regulation applicable from 25 May 2018.<sup>17</sup> The different processes of the  
152 FTC study and data pooling have been evaluated by ethics committees of the University of  
153 Helsinki (113/E3/01 and 346/E0/05), Helsinki University Central Hospital (136/E3/01,  
154 01/2011, 270/13/03/01/2008, 154/13/03/00/2011, HUS/1799/2017), and the Finnish Institute  
155 for Health and Welfare (THL/4743/6.02.04/2021). The FinnGen cohort consists of  
156 participants from Finnish biobanks. Participants in FinnGen provided informed consent for  
157 biobank research on the basis of the Finnish Biobank Act. Alternatively, separate research  
158 cohorts, collected before the Finnish Biobank Act came into effect (September 2013) and the  
159 start of FinnGen (August 2017), were collected based on study-specific consent and later  
160 transferred to the Finnish biobanks after approval by Fimea, the National Supervisory  
161 Authority for Welfare and Health. Further information related to ethical procedures and  
162 permits in the FinnGen study are provided in the Supplemental Material (under Supplemental  
163 Methods, page 2). The HUNT study was approved by the Regional Committee for Medical  
164 and Health Research Ethics (REC; 2019/29771), the Trøndelag Health Study, the Norwegian



165 Data Inspectorate, and the National Directorate of Health. All participants provided written  
166 informed consent. The authors assume responsibility for the accuracy and completeness of  
167 the protocol, data, and analyses, fidelity of their reporting, and compliance with the  
168 Declaration of Helsinki, national laws, and guidelines of the Finnish Advisory Board on  
169 Research Integrity.

## 170 ***Outcomes***

171 *LST*. For the validation analyses in the FTC, LST in hours per day (h/day) was used as the  
172 outcome and included self-reported television and video viewing and computer use at home.  
173 This outcome was selected to match exactly the outcome used in the base data for PGS LST.  
174 In the FTC, participants reported how many hours per day they spent sitting: at home  
175 watching TV or videos and at home at the computer. Each question had four choices: (a) less  
176 than an hour, (b) an hour–less than two hours, (c) two hours–less than four hours, and (d)  
177 four hours or more.<sup>18</sup> Answers were summarized to indicate LST (h/day). The data were  
178 collected in 2011 and represent screen time activities at that time.

179 *CVD*. The CVD categorization was based on FinnGen endpoint definitions. The following  
180 ICD-10 codes (ICD-9 codes [and FinnGen labels]) were used: All CVDs, I00-I99, T82.2,  
181 Z95.1 (390-459, 4019X, 4029A, 4029B, 4039A, 4040A, 4059A, 4059B, 4059X, 4160A,  
182 4330A, 4330X, 4331A, 4331X, 4339A, 4339X, 4340A, 4341A, 4349A, 4371, 4372, 4372A,  
183 4373, 4374, 4375, 4376, 4378X, and 9960A [I9\_CVD]); Hypertensive diseases, I10-I15,  
184 I27.0, I67.4 (4019X, 4029A, 4029B, 4039A, 4040A, 4059A, 4059B, 4059X, 4160A, and  
185 4372A [I9\_HYPERTENSION]), Ischemic heart diseases, I20-I25, T82.2, Z95.1 (410, 411[0-  
186 1], 412, 413, 414, 9960A [I9\_ISCHHEART]), and Cerebrovascular diseases, I60-I69 (430,  
187 431, 436, 438, 4330A, 4330X, 4331A, 4331X, 4339A, 4339X, 4340A, 4341A, 4349A, 4371,  
188 4372, 4373, 4374, 4375, 4376, and 4378X [I9\_CEREBVASC]). The register data were based

189 on the national hospital discharge (available from 1968) and causes of death (available from  
190 1969) registers. Additionally, any CVDs included data from Care Register for Health Care  
191 for coronary angioplasty, coronary artery bypass, valvular operations, endovascular or  
192 surgical operations to intracerebral aneurysms, and peripheral artery operations and from the  
193 Finnish Social Insurance Institution drug reimbursement register for atrial fibrillation and  
194 flutter, heart failure, and hypertension. Hypertensive diseases also included data from the  
195 drug reimbursement register. Further descriptive information, such as disease prevalence and  
196 age distribution, can be queried using FinnGen labels via the Risteys interface  
197 ([risteys.finregistry.fi](http://risteys.finregistry.fi)). We utilized the same ICD-10 and ICD-9 codes in the HUNT  
198 replication analyses. The HUNT health records are based on the Nord-Trøndelag Health  
199 Trust discharge register (available from 1987).

## 200 *Exposure*

201 The PGS LST was based on the largest available GWAS meta-analysis for LST at the time of  
202 the analysis (GWAS Catalog Study ID: GCST90104339).<sup>19</sup> In this data, the LST included  
203 self-reported television viewing, video game playing, and computer use at home. The  
204 discovery data reportedly explained 2.8% of the variance in self-reported LST,<sup>19</sup> and the SNP  
205 heritability was 7.4%.<sup>20</sup> The base data did not overlap with the later used FTC, FinnGen or  
206 HUNT study cohorts.

207 We used the high-performing SbayesR approach to construct the PGS.<sup>21</sup> In SbayesR, the base  
208 data summary statistics are re-weighted to consider the linkage disequilibrium between each  
209 variant and restricted to HapMap3 SNPs to ensure computational efficiency while  
210 representing the whole genome. The pipeline and relevant codes are available elsewhere.<sup>22</sup>  
211 The final number of processed variants was 890,575 in the FTC, 891,628 in the FinnGen  
212 cohort, and 901,640 in the HUNT cohort. We used standardized PGS LST scores (mean of

213 zero, standard deviation of one) in the analyses. The PGS LST fitted well to the FTC,  
214 FinnGen, and HUNT cohorts and followed a normal distribution.

### 215 **Genotyping, quality control, and imputation**

216 In the FTC, chip genotyping was done using Illumina Human610-Quad v1.0 B, Human670-  
217 QuadCustom v1.0 A, Illumina HumanCoreExome, and Affymetrix FinnGen Axiom arrays.  
218 Genotype quality control was done in three batches (batch1: 610k+670k chip, batch2:  
219 HumanCoreExome, and batch3: Affymetrix chip genotypes), and genotypes of all batches  
220 were imputed to the Haplotype Reference Consortium release 1.1 reference panel.<sup>23</sup> More  
221 details related to genotyping procedures in the FTC are available in the Supplemental  
222 Material (Supplemental Methods, page 2).

223 The FinnGen samples were genotyped with Illumina and Affymetrix chip arrays (Illumina  
224 Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA). A detailed  
225 information on genotyping, quality control, and imputation has been described elsewhere:  
226 <https://finngen.gitbook.io/documentation/>.

227 In the HUNT study, a total of ~69,000 participants contributed with DNA for genotyping in  
228 HUNT2 and HUNT3. Detailed information on genotyping, imputation, and quality control is  
229 described in more detail elsewhere.<sup>24</sup>

### 230 ***Covariates***

231 Covariates were based on previous literature.<sup>25,26</sup> The first ten principal components of  
232 ancestry adjust for any genetic stratification that may occur in the study population and were  
233 used alongside with sex as a covariate in all analyses.<sup>25</sup> Additional covariates were specific to  
234 the analysis. In validation analyses in the FTC, we also used age, educational attainment  
235 (highest achieved self-reported educational degree in the Finnish educational system; low,

236 basic education degree at most; middle, basic education and additional studies; and high, at  
237 least upper secondary degree),<sup>27</sup> and body mass index (BMI) based on valid self-reported  
238 height and weight.<sup>28</sup> In main and replication analyses, we also used genotyping batch, which  
239 accounts for the potential stratification that may occur from the genotyping array and sample.  
240 In further exploratory analyses with the replication cohort, we controlled for variance caused  
241 by highly plausible covariates, such as BMI (based on measured height and weight [Jenix  
242 DS-102, Dong Sahn Jenix Co, Ltd, Korea]), socioeconomic status (SES; derived from  
243 occupational status),<sup>26</sup> and self-reported smoking status (never, former, current) using the  
244 HUNT3 data.

#### 245 *Statistical analysis*

246 *Validation analyses.* All validation analyses were performed with Stata (StataCorp, College  
247 Station, TX, USA). Correlation between PGS LST and self-reported LST was tested with  
248 Pearson correlation. The association between PGS LST and self-reported LST was assessed  
249 with linear regression in the FTC, where the twin structure of the data was acknowledged  
250 using the svyset command (i.e., the twin pair was the primary sampling unit). The crude  
251 model included standardized PGS LST and the first ten principal components of ancestry.  
252 Model 1 was adjusted additionally for age and sex, and Model 2 was further adjusted with  
253 educational attainment and BMI. Differences between high and low genetic liabilities were  
254 evaluated using linear regression, where a binary variable indicated whether the individual  
255 belonged to the highest or lowest decile of PGS LST. A priori power calculations indicated  
256 that sufficient statistical power would be reached with a sample size of  $N > 950$  (expected  
257 small effect size 0.02, 15 predictors, power at 0.8 level, and  $\alpha$  set to 0.05).

258 *Main analyses.* We used Cox proportional hazard models and R packages `survival`<sup>29</sup> and  
259 `survminer`<sup>30</sup> to estimate the hazard ratios (HRs) and 95% confidence intervals (CI) between

260 PGS LST and incident CVD in the FinnGen cohort. Visual inspection of Schoenfeld residuals  
261 and log-minus-log plots indicated that the finally adjusted models satisfy the proportional  
262 hazard assumptions.<sup>31</sup> PGS×SEX interaction was tested, but no replicable sex differences  
263 were observed; thus, analyses were conducted for men and women in combination. We used  
264 age as the time scale and the first ten principal components of ancestry, genotyping batch,  
265 and sex as covariates. Start of follow-up was set at birth, as the PGS remains stable from  
266 conception. Follow-up ended with whichever came first among the first record of the  
267 endpoint of interest, death, or the end of follow-up on 31 December 2021. Utilizing the  
268 weights of the European standard population, age-standardized incidence was calculated  
269 when relevant.<sup>32</sup> We also compared the hazard ratios (relative measures of survival) and  
270 cohort-specific cumulative incidence of events (absolute measures of survival) between the  
271 highest and lowest deciles of PGS LST. We additionally conducted competing risk analysis  
272 with Fine-Gray sub-distribution hazard models for the three main CVDs, as one event may  
273 preclude the occurrence of another. Here, we coded censored as “0,” events of interest as “1,”  
274 and other competing CVD events as “2”.<sup>33</sup> Additionally, as the exposure (PGS LST) might  
275 affect who survives until genotyping and also to control for immortal time bias, we conducted  
276 sensitivity analyses in which the start of the follow-up was set to the date of individual DNA  
277 sampling. Sufficient statistical power was expected to be achieved with > 120 cases, using a  
278 classical definition of 10 cases per predictor variable.

279 *Replication analyses.* The replication analyses were conducted in HUNT and followed a  
280 similar procedure as the main survival analyses, except that when mortality data were not  
281 available, the end of follow-up was assigned to whichever came first between the first record  
282 of the endpoint of interest and last verified contact with healthcare.

283 *Exploratory analyses.* In HUNT, we also conducted several exploratory analyses to assess the

284 potential sources of observations in the main and replication analyses. We tested if the  
285 associations were independent of highly plausible covariates with a complete case subsample  
286 of HUNT3. In this analysis, Model 1 included PGS LST, the first ten principal components of  
287 ancestry, sex, and genotyping batch while Model 2 included additionally SES, Model 3  
288 additionally BMI, and Model 4 additionally smoking status. We also tested a potential  
289 mediating pathway from PGS LST to incident CVD via sedentary behavior using the product  
290 of coefficients approach and accompanying Sobel test, which are suitable for survival  
291 analysis with common outcomes.<sup>34</sup> In this mediation analysis, we used participants from the  
292 sensitivity analyses with self-reported total sitting time (h/day): “About how many hours do  
293 you sit during an average day? (include work hours and leisure time)”. Only diseases for  
294 which a direct association between PGS LST and incident disease was observed in the  
295 sensitivity analyses were included in the mediation analysis. Association between PGS LST  
296 and total sitting time were evaluated with linear regression, while a Cox proportional hazards  
297 model was used for the association between total sitting time and disease incidence. The  
298 models were adjusted for sex similar to prior sensitivity analyses but not for the first ten  
299 principal components or genotyping batch for consistency across pathways. These mediating  
300 analyses were replicated with a physical activity variable, i.e., metabolic equivalent (MET)  
301 hours per week, calculated as the product of self-reported physical activity frequency,  
302 intensity, and duration. Across all analyses, all tests were two-tailed, and  $\alpha$  was set at  $p <$   
303 0.05.

## 304 **Results**

### 305 *Association between polygenic score for leisure screen time and self-reported leisure screen* 306 *time*

307 The 2,689 individuals of the FTC reported an average of  $3.9 \pm 1.1$  hours LST per day (Table  
308 S2). The effect size for PGS LST against LST was small (Pearson correlation coefficient =

309 0.08,  $p < 0.001$ ), and PGS LST explained 0.7% of the variance in the LST. PGS LST of one  
310 standard deviation higher was associated with higher self-reported LST (h/day), with  $\beta = 0.09$   
311 (95% CI: 0.05–0.14) in crude models;  $\beta = 0.09$  (95% CI: 0.05–0.13) after adjustments for  
312 age, and sex; and  $\beta = 0.08$  (95% CI: 0.04–0.13) after further adjustments for educational  
313 attainment and BMI (Table S3). Correspondingly, individuals in the highest decile for PGS  
314 LST reported an average of  $4.1 \pm 1.0$  h/day LST, while those in the lowest decile reported an  
315 average of 3.7 (1.1) h/day ( $p < 0.001$  for difference) (Table S4).

316 *Association between polygenic score for leisure screen time and cardiovascular disease*  
317 *incidence*

318 Descriptive data on 293,250 participants in the FinnGen sample of any CVD are shown in  
319 Table 1. Fifty-eight percent in the FinnGen cohort were diagnosed with a CVD in adulthood  
320 ( $\geq 40$  years old, 168,770 cases) with an age-standardized incidence of 34.9 per 10,000  
321 person-years (Figure 2). The average follow-up time from birth was 58 (40 to 106) years,  
322 with a total of 17,101,133 person-years. The descriptives of 35,289 participants in the HUNT  
323 replication cohort are presented in Table 1. The age-standardized incidence for any CVD was  
324 36.5 per 10,000 person-years (Figure 2), with an average follow-up time of 64 (40 to 103)  
325 years and a total of 2,257,493 person-years.

326 In FinnGen, PGS LST of one standard deviation higher was associated with a higher risk of  
327 any CVD after adjusting for the first ten principal components of ancestry, sex, and  
328 genotyping batch (HR: 1.05, 95% CI: 1.05–1.06; Figure 2). Disease-specific associations for  
329 three most common CVDs were 1) 1.09 (1.08 – 1.09) for hypertensive diseases (108,040  
330 cases), 2) 1.06 (1.05 – 1.07) for ischemic heart diseases (64,724 cases), and 3) 1.05 (1.04–  
331 1.06) for cerebrovascular diseases (34,170 cases). The associations were replicated in the  
332 HUNT cohort with exactly or very similar effect sizes (Figure 2).

333 In the FinnGen cohort, those in the highest PGS LST decile had 19% to 35% higher risk of  
334 CVDs compared to those in the lowest PGS LST decile (Table S5). For example, at 60 years  
335 of age, the cumulative incidence for any CVDs was 44% for those with high PGS LST, while  
336 for those with low PGS LST it was 37% (Table S7, Figure 3). This higher risk of incident  
337 CVD in participants with higher genetic liability replicated in HUNT, except for  
338 cerebrovascular disease (HR: 1.08 [0.96–1.20]) (Table S6, Figure S1).

339 Considering other CVDs as competing events attenuated the cumulative incidence estimates  
340 for both high and low PGS LST participants, but their difference remained statistically  
341 significant for hypertensive diseases and ischemic heart diseases, although not for  
342 cerebrovascular diseases (Table S8). In further sensitivity analyses with follow-up starting  
343 from individual DNA sampling dates (mean follow-up was 6.0 years in FinnGen and 5.0 in  
344 HUNT), the associations remained the same or were slightly attenuated in the FinnGen  
345 cohort, and replicated in the HUNT cohort except for any CVD and cerebrovascular diseases  
346 (Table S9).

347 Exploratory analyses showed that the association between PGS LST and incident CVD  
348 persisted after adjustments for SES, BMI, and smoking status, except for cerebrovascular  
349 diseases, where the number of cases was smallest (Figure S2). Mediation analysis showed  
350 that higher PGS LST was associated with higher self-reported total sitting time (h/day) in the  
351 HUNT cohort ( $\beta = 0.06$ , standard error [SE] = 0.02,  $p = 0.016$  in a model for hypertensive  
352 diseases and  $\beta = 0.07$ , SE = 0.02,  $p = 0.003$  for ischemic heart diseases) but indicated no  
353 potential mediating pathway to incident CVD (Figure S3). However, higher PGS LST was  
354 also associated with lower MET h/week ( $\beta = -0.54$ , SE = 0.09,  $p < 0.001$  for hypertensive  
355 diseases and  $\beta = -0.47$ , SE = 0.09,  $p < 0.001$  for ischemic heart diseases), while higher MET  
356 h/week was associated with lower risk of hypertensive and ischemic heart diseases ( $\beta = -0.01$ ,



357 SE = 0.00,  $p < 0.001$  and  $\beta = -0.01$ , SE = 0.00,  $p = 0.005$ , respectively), thus indicating a  
358 potential mediating pathway through reduction in physical activity.

## 359 **Discussion**

360 We found that higher genetic liability to LST was associated with more self-reported LST  
361 and that the genetic liability to LST also increased the risk of incident CVD, with replicable  
362 findings across two independent large populations. The observed effect sizes remained  
363 relatively small and attenuated after adjustment, but suggest that the observed adverse health  
364 effects may be either directly attributable to genetic effects or mediated by reduced levels of  
365 physical activity.

366 The underlying role of genetics in sedentary behavior and morbidity has so far been  
367 understudied.<sup>8</sup> Evolution has a profound influence on human biology; hence, evolution-based  
368 theories provide valuable insights into epidemiology and population health. Evolutionary  
369 selection processes may explain why the “desire to be sedentary is in our genes” and also  
370 why previously advantageous alleles may currently be disease-causing alleles.<sup>9,10,35</sup> In our  
371 study, the risk of any CVD increased very consistently by 5% per standard deviation increase  
372 in the PGS LST. Furthermore, we observed that the risk of CVD differs significantly between  
373 those in the highest and lowest deciles of PGS LST. Those with high PGS LST had 21%  
374 (19% to 24%) higher risk for any CVD than those with low PGS LST. Those with high PGS  
375 LST also indicated higher cumulative disease incidences at different ages, therefore showing  
376 lower probability for survival. For example, at the age of 60, those with a high PGS LST had  
377 a 7% higher cumulative incidence for any CVD compared to those with a low PGS LST. The  
378 associations were statistically independent of SES, BMI, and smoking, although adjustment  
379 for these factors attenuated the associations. One explanation for these findings may be  
380 genetic pleiotropy.

381

382 In genetic pleiotropy, the same genes would affect both LST and CVD. This theory is  
383 supported by previously published genetic correlations between LST and several CVD-  
384 related phenotypes (0.24 for coronary artery disease, 0.32 for overweight, 0.22 for type 2  
385 diabetes, -0.26 for high-density lipoprotein cholesterol, and 0.27 for triglycerides), indicating  
386 shared genetic material.<sup>19</sup> Previous studies suggest that most robust pleiotropic genes are  
387 associated with function of the nervous system, e.g., the DLG4 gene (ENSG00000132535) is  
388 associated with synaptic function in the brain, pituitary gland, and retina.<sup>36,37</sup> Overall, the  
389 tissue enrichment analyses suggest that currently known genes associated with LST are  
390 expressed mainly in the nervous system, specifically in the brain.<sup>19</sup> However, more studies  
391 are needed to further elucidate the underlying mechanism between genetic predisposition to  
392 LST and the onset of CVDs.

393 Our mediation analysis suggests that there may also be an alternative pathway in which  
394 sedentary genes contribute to inadequate levels of physical activity, thereby increasing the  
395 risk of incident CVD. Much has been written about the benefits of physical activity on  
396 cardiovascular health,<sup>38</sup> with our findings bringing new perspectives to this discussion. The  
397 planning and implementation of public health interventions in different settings (e.g., schools,  
398 workplaces, communities) will benefit from an understanding of the inherent biological  
399 tendencies of the population.<sup>39</sup> Considering that genetics contribute to sedentary behavior,  
400 effective strategies should emphasize environmental planning that nudges people to be active  
401 and/or interventions that significantly nourish the intrinsic reward system.<sup>40</sup> Moving from  
402 sedentary to active behavior may confer health benefits, as the human evolutionary  
403 background may also explain why physiological functions operate optimally under regular  
404 physical activity.<sup>41</sup>

405 The observed coefficient of determination and effect size between PGS LST and self-  
406 reported LST were small, thus potentially raising concerns how well the score reflects genetic  
407 liability to this trait. As there is little prior evidence on how PGSs are associated to sedentary  
408 behavior while some data are available for physical activity, we discuss our findings aligned  
409 to this construct. Our results are consistent with previous studies in which physical activity  
410 PGSs were associated with the corresponding trait and differentiated well the extreme ends of  
411 the genetic spectrum, but explain only a small proportion (0.0–1.4%) of the phenotypic  
412 variance.<sup>26,42</sup> This is an interesting contrast and may suggest that current PGSs are not fully  
413 able to quantify all the genetic effects they detect. A plausible explanation for the small  
414 variances were assumed to be the heterogeneity in phenotype assessment (i.e., physical  
415 activity collected through varying methods). However, in our study, we carefully selected the  
416 validation data to mimic the phenotype in the base data. Nevertheless, the fraction of variance  
417 explained remained small and may indicate other methodological limitations related to  
418 polygenic scoring. One of these is the “missing heritability” dilemma. Missing heritability is  
419 the difference between the observed SNP heritability and heritability estimates based on twin  
420 studies. In our case, this is estimated to be at least 22%<sup>43–45</sup> and potentially caused by the  
421 following: inflated family-based estimates,<sup>46</sup> relatively small sample sizes of current  
422 GWASs,<sup>47</sup> inadequate accuracy in phenotyping of the trait of interest, and/or the lack of  
423 information on less common and rare variants in genotyping arrays used in GWAS studies.  
424 More detailed coverage of the variation in the genome by whole genome sequencing is  
425 expected to reduce missing heritability.<sup>48,49</sup>

## 426 **Strengths and limitations**

427 This study has several strengths. We used high-performing and genome-wide methods for  
428 genetic scoring and showed the scores to be valid with independent data sets. We used the  
429 most comprehensive data available and a robust study design, which included a replication

430 cohort. We further tested the robustness of our findings with multiple approaches, with  
431 consistent findings supporting our conclusions. We also acknowledge that our results should  
432 be interpreted with the following limitations in mind. The base data for PGS LST is based on  
433 self-reported LST which may be subject to biases from recall, cultural differences, and social  
434 desirability.<sup>50</sup> Notably, the LST represented screen time activities at the time of the data  
435 collection (2011) with limited generalizability to the modern era. The ability to replicate  
436 genetic variants related to LST across cohorts remains a challenge, and more quality GWASs  
437 regarding sedentary behavior are required.<sup>36</sup> The data were based on individuals with  
438 European ancestry. Hence, replication studies using other populations are required. The  
439 FinnGen did not have data related to sedentary behavior or physical activity, and therefore,  
440 the mediation analyses could not be conducted in this cohort. The used FinnGen and HUNT  
441 may be enriched with CVDs due to participants having had an established contact with  
442 healthcare services.

#### 443 **Conclusions**

444 The findings of this study confirm our hypothesis that higher genetic liability for sedentary  
445 behavior is associated with a greater risk of developing CVD, although effect sizes with the  
446 current data and methods remain small.

#### 447 *Acknowledgements*

448 We thank the participants and all those who contributed to the data collection from the FTC,  
449 FinnGen, and HUNT cohorts without whom this study would not be possible. The detailed  
450 list of investigators involved in the FinnGen is available on page 12 of the Supplemental  
451 Material.

452 **Sources of Funding**

453 **Funding** The funders were not involved in planning, analyzing, or drafting the manuscript in  
454 any way. The study and FTC data collection were funded by the Research Council of Finland  
455 (grants 341750, 346509 and 361981 to ES, grants 265240, 263278, 100499, 205585, 118555,  
456 141054, 264146, 308248, 312073, 336823, and 352792 to JK); the Juho Vainio Foundation  
457 to ES; the Päivikki and Sakari Sohlberg Foundation to ES; and the Sigrid Juselius  
458 Foundation, the Wellcome Trust Sanger Institute, the Broad Institute, and the European  
459 Network for Genetic and Genomic Epidemiology to JK.

460 The FinnGen project is funded by Business Finland and thirteen international pharmaceutical  
461 industry partners: AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-  
462 Myers Scibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics,  
463 MSD/Merck, Novartis, Pfizer, and Sanofi.

464 The HUNT study is a collaboration between HUNT Research Center (Faculty of Medicine  
465 and Health Sciences, Norwegian University of Science and Technology, NTNU), Trøndelag  
466 County Council, Central Norway Regional Health Authority, and the Norwegian Institute of  
467 Public Health. The genotyping in HUNT was financed by the National Institutes of Health;  
468 University of Michigan; the Research Council of Norway; the Liaison Committee for  
469 Education, Research and Innovation in Central Norway; and the Joint Research Committee  
470 between St. Olav's hospital and the Faculty of Medicine and Health Sciences, NTNU. The  
471 genetic investigations of the HUNT study are a collaboration between researchers from the  
472 KG Jebsen Center for Genetic Epidemiology, NTNU, the University of Michigan Medical  
473 School, and the University of Michigan School of Public Health. The KG Jebsen Center for  
474 Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen, Faculty of Medicine  
475 and Health Sciences, NTNU, Norway.

476 **Disclosures**

477 **Competing interests.** The authors declare no competing interests.

478 **Data sharing.** The utilized FTC subsample data are in the Biobank of the National Institute  
479 for Health and Welfare. Data are available for qualified researchers through a standardized  
480 application procedure (see the website <https://thl.fi/en/web/thl-biobank/for-researchers> for  
481 details).

482 Access to individual-level genotypes and register data from FinnGen participants can be  
483 applied via the Fingenious portal (<https://site.fingenious.fi/en/>) hosted by the Finnish Biobank  
484 Cooperative FinBB (<https://finbb.fi/en/>). The register data also needs permission from  
485 FinData ([www.findata.fi](http://www.findata.fi)).

486 Researchers affiliated with a Norwegian research institution can apply for HUNT data access  
487 from the HUNT Research Centre ([www.ntnu.edu/hunt](http://www.ntnu.edu/hunt)) if they have obtained project approval  
488 from the Regional Committee for Medical and Health Research Ethics (REC). Researchers  
489 not affiliated with a Norwegian research institution should collaborate with and apply  
490 through a Norwegian principal investigator. Information on the application and conditions for  
491 data access is available online ([www.ntnu.edu/hunt/data](http://www.ntnu.edu/hunt/data)). The HUNT Databank website  
492 provides a detailed overview of the available variables in HUNT  
493 ([www.ntnu.edu/hunt/databank](http://www.ntnu.edu/hunt/databank)). Certain data from ancillary HUNT projects may be subject to  
494 a time-limited exclusivity provided to the researchers who have financed and conducted the  
495 data collection. Biological material is available for analyses, and information on procedures  
496 is found on the HUNT Biobank website ([www.ntnu.edu/hunt/hunt-biobank](http://www.ntnu.edu/hunt/hunt-biobank)). Data from the  
497 health registries are not kept by HUNT; instead, linkages between HUNT and registry data  
498 must be made for each research project and require that the principal investigator has  
499 obtained project-specific approval for such linkage from REC and each registry owner.

500 **Contributorship** LJ and ES conceptualized the research question, study design, and  
501 statistical analysis. KK, UE, and JK made significant contributions to the final analysis  
502 design. LJ prepossessed the polygenic score data under the supervision of TP and  
503 implemented the scores to the FTC, FinnGen, and HUNT study cohorts with the help of TP,  
504 KK, and NT. LJ performed the statistical modelling under supervision of ES and with  
505 consultation from NT. JK and TP participated in FTC data collection and management, while  
506 AB, MK, KØ, and UW to HUNT data. LJ drafted the first version of the manuscript, and all  
507 authors contributed significantly to the writing, critical interpretation of the findings, and  
508 revising the manuscript. ES acquired funding for the study. The corresponding author attests  
509 that all listed authors meet authorship criteria and that no others meeting the criteria have  
510 been omitted.  
511

## 512 References

- 513 1. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-  
514 Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national disability-adjusted  
515 life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE)  
516 for 195 countries and territories, 1990–2017: a systematic analysis for the Global  
517 Burden of Disease Study 2017. *The Lancet*. 2018;392:1859–1922.
- 518 2. On behalf of SBRN Terminology Consensus Project Participants, Tremblay MS, Aubert  
519 S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, Chastin SFM, Altenburg  
520 TM, Chinapaw MJM. Sedentary Behavior Research Network (SBRN) – Terminology  
521 Consensus Project process and outcome. *Int. J. Behav. Nutr. Phys. Act.* 2017;14:75.
- 522 3. Husu P, Suni J, Vähä-Ypyä H, Sievänen H, Tokola K, Valkeinen H, Mäki-Opas T,  
523 Vasankari T. Objectively measured sedentary behavior and physical activity in a sample  
524 of Finnish adults: a cross-sectional study. *BMC Public Health*. 2016;16:920.
- 525 4. Yang L, Cao C, Kantor ED, Nguyen LH, Zheng X, Park Y, Giovannucci EL, Matthews  
526 CE, Colditz GA, Cao Y. Trends in Sedentary Behavior Among the US Population,  
527 2001-2016. *JAMA*. 2019;321:1587.
- 528 5. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA.  
529 Sedentary Time and Its Association With Risk for Disease Incidence, Mortality, and  
530 Hospitalization in Adults: A Systematic Review and Meta-analysis. *Ann. Intern. Med.*  
531 2015;162:123–132.
- 532 6. Ekelund U, Brown WJ, Steene-Johannessen J, Fagerland MW, Owen N, Powell KE,  
533 Bauman AE, Lee I-M. Do the associations of sedentary behaviour with cardiovascular  
534 disease mortality and cancer mortality differ by physical activity level? A systematic  
535 review and harmonised meta-analysis of data from 850 060 participants. *Br. J. Sports*  
536 *Med.* 2019;53:886–894.
- 537 7. Raichlen DA, Lieberman DE. The evolution of human step counts and its association  
538 with the risk of chronic disease. *Curr. Biol.* 2022;32:R1206–R1214.
- 539 8. Young DR, Hivert M-F, Alhassan S, Camhi SM, Ferguson JF, Katzmarzyk PT, Lewis  
540 CE, Owen N, Perry CK, Siddique J, et al. Sedentary Behavior and Cardiovascular  
541 Morbidity and Mortality: A Science Advisory From the American Heart Association.  
542 *Circulation* [Internet]. 2016 [cited 2024 Mar 19];134. Available from:  
543 <https://www.ahajournals.org/doi/10.1161/CIR.0000000000000440>
- 544 9. Lea AJ, Clark AG, Dahl AW, Devinsky O, Garcia AR, Golden CD, Kamau J, Kraft TS,  
545 Lim YAL, Martins D, et al. Evolutionary mismatch and the role of GxE interactions in  
546 human disease. 2023 [cited 2023 Aug 28]; Available from:  
547 <https://arxiv.org/abs/2301.05255>
- 548 10. Kirkwood TBL, Austad SN. Why do we age? *Nature*. 2000;408:233–238.
- 549 11. Manus MB. Evolutionary mismatch. *Evol. Med. Public Health*. 2018;2018:190–191.
- 550 12. Byars SG, Voskarides K. Antagonistic Pleiotropy in Human Disease. *J. Mol. Evol.*  
551 2020;88:12–25.



- 552 13. Choi SW, Mak TS-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score  
553 analyses. *Nat. Protoc.* 2020;15:2759–2772.
- 554 14. Kaprio J, Bollepalli S, Buchwald J, Iso-Markku P, Korhonen T, Kovanen V, Kujala U,  
555 Laakkonen EK, Latvala A, Leskinen T, et al. The Older Finnish Twin Cohort - 45 Years  
556 of Follow-up. *Twin Res. Hum. Genet.* 2019;22:240–254.
- 557 15. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP,  
558 Laivuori H, Aavikko M, Kaunisto MA, et al. FinnGen provides genetic insights from a  
559 well-phenotyped isolated population. *Nature.* 2023;613:508–518.
- 560 16. Krokstad S, Sund ER, Kvaløy K, Rangul V, Næss M. HUNT for better public health.  
561 *Scand. J. Public Health.* 2022;50:968–971.
- 562 17. Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, Güneş O, Hall P,  
563 Hayhurst J, et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition  
564 resource. *Nucleic Acids Res.* 2023;51:D977–D985.
- 565 18. Piirtola M, Kaprio J, Ropponen A. A Study of Sedentary Behaviour in the Older Finnish  
566 Twin Cohort: A Cross Sectional Analysis. *BioMed Res. Int.* 2014;2014:1–9.
- 567 19. Wang Z, Emmerich A, Pillon NJ, Moore T, Hemerich D, Cornelis MC, Mazzaferro E,  
568 Broos S, Ahluwalia TS, Bartz TM, et al. Genome-wide association analyses of physical  
569 activity and sedentary behavior provide insights into underlying mechanisms and roles  
570 in disease prevention. *Nat. Genet.* 2022;54:1332–1344.
- 571 20. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Bulik-Sullivan  
572 BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, Neale  
573 BM. LD Score regression distinguishes confounding from polygenicity in genome-wide  
574 association studies. *Nat. Genet.* 2015;47:291–295.
- 575 21. Lloyd-Jones LR, Zeng J, Sidorenko J, Yengo L, Moser G, Kemper KE, Wang H, Zheng  
576 Z, Magi R, Esko T, et al. Improved polygenic prediction by Bayesian multiple  
577 regression on summary statistics. *Nat. Commun.* 2019;10:5086.
- 578 22. Herranen P, Palviainen T, Rantanen T, Tiainen K, Viljanen A, Kaprio J, Sillanpää E. A  
579 Polygenic Risk Score for Hand Grip Strength Predicts Muscle Strength and Proximal  
580 and Distal Functional Outcomes among Older Women. *Med. Sci. Sports Exerc.*  
581 2022;54:1889–1896.
- 582 23. The Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for  
583 genotype imputation. *Nat. Genet.* 2016;48:1279–1283.
- 584 24. Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, Wolford B,  
585 Zhou W, Nielsen JB, Holmen OL, et al. The HUNT study: A population-based cohort  
586 for genetic research. *Cell Genomics.* 2022;2:100193.
- 587 25. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal  
588 components analysis corrects for stratification in genome-wide association studies. *Nat.*  
589 *Genet.* 2006;38:904–909.

- 590 26. Tynkkynen NP, Törmäkangas T, Palviainen T, Hyvärinen M, Klevjer M, Joensuu L,  
591 Kujala U, Kaprio J, Bye A, Sillanpää E. Associations of polygenic inheritance of  
592 physical activity with aerobic fitness, cardiometabolic risk factors and diseases: the  
593 HUNT study. *Eur. J. Epidemiol.* [Internet]. 2023 [cited 2023 Aug 22]; Available from:  
594 <https://link.springer.com/10.1007/s10654-023-01029-w>
- 595 27. Joensuu L, Waller K, Kankaanpää A, Palviainen T, Kaprio J, Sillanpää E. Genetic  
596 Liability to Cardiovascular Disease, Physical Activity, and Mortality: Findings from the  
597 Finnish Twin Cohort. *Med. Sci. Sports Exerc.* [Internet]. 2024 [cited 2024 Jun  
598 20]; Available from: <https://journals.lww.com/10.1249/MSS.0000000000003482>
- 599 28. Tuomela J, Kaprio J, Sipilä PN, Silventoinen K, Wang X, Ollikainen M, Piirtola M.  
600 Accuracy of self-reported anthropometric measures — Findings from the Finnish Twin  
601 Study. *Obes. Res. Clin. Pract.* 2019;13:522–528.
- 602 29. Therneau T. survival: Survival Analysis. Version 3.5-8 [Internet]. [cited 2024 Feb  
603 14]; Available from: <https://cran.r-project.org/web/packages/survival/index.html>
- 604 30. Alboukadel K, Marcin K, Przemyslaw B, Scheipl F. survminer: Drawing Survival  
605 Curves using “ggplot2”. Version 0.4.9. [Internet]. [cited 2024 Feb 14]; Available from:  
606 <https://cran.r-project.org/web/packages/survminer/index.html>
- 607 31. Vaura F, Kauko A, Suvila K, Havulinna AS, Mars N, Salomaa V, FinnGen, Cheng S,  
608 Niiranen T. Polygenic Risk Scores Predict Hypertension Onset and Cardiovascular  
609 Risk. *Hypertension.* 2021;77:1119–1127.
- 610 32. Pace M, Cayotte E, Agafitei L, Zupanic T, Wojtyniak B, Gissler M, Lanzieri G,  
611 Glickman M, Grande E. Revision of the European Standard Population: report of  
612 Eurostat’s task force : 2013 edition. 2013 ed. Luxembourg: Publications Office; 2013.
- 613 33. Competing Risks Cumulative Incidence [Internet]. Tidycmprsk 100. [cited 2024 Jun  
614 6]; Available from: <https://mskcc-epi-bio.github.io/tidycmprsk/reference/cuminc.html>
- 615 34. VanderWeele TJ. Causal Mediation Analysis With Survival Data. *Epidemiology.*  
616 2011;22:582–585.
- 617 35. Speakman JR. An Evolutionary Perspective on Sedentary Behavior. *BioEssays.*  
618 2020;42:1900156.
- 619 36. Van De Vegte YJ, Said MA, Rienstra M, Van Der Harst P, Verweij N. Genome-wide  
620 association studies and Mendelian randomization analyses for leisure sedentary  
621 behaviours. *Nat. Commun.* 2020;11:1770.
- 622 37. The Human Protein Atlas: DLG4 [Internet]. [cited 2023 Oct 31]; Available from:  
623 <https://www.proteinatlas.org/ENSG00000132535-DLG4>
- 624 38. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann  
625 Smith C, Wilkins E, Rayner M, et al. Quantifying the Association Between Physical  
626 Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta-  
627 Analysis. *J. Am. Heart Assoc.* 2016;5:e002495.

- 628 39. Bauman AE, Reis RS, Sallis JF, Wells JC, Loos RJ, Martin BW. Correlates of physical  
629 activity: why are some people physically active and others not? *The Lancet*.  
630 2012;380:258–271.
- 631 40. Lieberman DE. Is Exercise Really Medicine? An Evolutionary Perspective: *Curr.*  
632 *Sports Med. Rep.* 2015;14:313–319.
- 633 41. Eaton SB, Eaton SB. An evolutionary perspective on human physical activity:  
634 implications for health. *Comp. Biochem. Physiol. A. Mol. Integr. Physiol.*  
635 2003;136:153–159.
- 636 42. Kujala UM, Palviainen T, Pesonen P, Waller K, Sillanpää E, Niemelä M, Kangas M,  
637 Vähä-Ypyä H, Sievänen H, Korpelainen R, et al. Polygenic Risk Scores and Physical  
638 Activity. *Med. Sci. Sports Exerc.* 2020;52:1518–1524.
- 639 43. Hoed MD, Brage S, Zhao JH, Westgate K, Nessa A, Ekelund U, Spector TD, Wareham  
640 NJ, Loos RJ. Heritability of objectively assessed daily physical activity and sedentary  
641 behavior. *Am. J. Clin. Nutr.* 2013;98:1317–1325.
- 642 44. Van Der Aa N, Bartels M, Te Velde SJ, Boomsma DI, De Geus EJC, Brug J. Genetic  
643 and Environmental Influences on Individual Differences in Sedentary Behavior During  
644 Adolescence: A Twin-Family Study. *Arch. Pediatr. Adolesc. Med.* [Internet]. 2012  
645 [cited 2023 Oct 30];166. Available from:  
646 <http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/archpediatrics.2011.1658>
- 647 45. Nelson MC, Gordon-Larsen P, North KE, Adair LS. Body Mass Index Gain, Fast Food,  
648 and Physical Activity: Effects of Shared Environments over Time\*. *Obesity*.  
649 2006;14:701–709.
- 650 46. Muñoz M, Pong-Wong R, Canela-Xandri O, Rawlik K, Haley CS, Tenesa A. Evaluating  
651 the contribution of genetics and familial shared environment to common disease using  
652 the UK Biobank. *Nat. Genet.* 2016;48:980–983.
- 653 47. Young AI. Solving the missing heritability problem. *PLOS Genet.* 2019;15:e1008222.
- 654 48. Jang S-K, Evans L, Fialkowski A, Arnett DK, Ashley-Koch AE, Barnes KC, Becker  
655 DM, Bis JC, Blangero J, Bleecker ER, et al. Rare genetic variants explain missing  
656 heritability in smoking. *Nat. Hum. Behav.* 2022;6:1577–1586.
- 657 49. Wainschtein P, Jain D, Zheng Z, TOPMed Anthropometry Working Group, Aslibekyan  
658 S, Becker D, Bi W, Brody J, Carlson JC, Correa A, et al. Assessing the contribution of  
659 rare variants to complex trait heritability from whole-genome sequence data. *Nat. Genet.*  
660 2022;54:263–273.
- 661 50. Choi BCK, Pak AWP. A catalog of biases in questionnaires. *Prev. Chronic. Dis.*  
662 2005;2:A13.

663

664 **Table**

665 Table 1. Descriptives of individuals with any CVD in the main FinnGen cohort and in the  
666 replication cohort (HUNT).

Characteristic	Main cohort		Replication cohort	
	N	FinnGen	N	HUNT
Age (years)	293,250	67.0 (13.0)	35,289	64.0 (13.1)
Female (%)	293,250	52.3	18,218	51.6
BMI (kg/m <sup>2</sup> )	82,224	27.8 (5.3)	22,398	27.9 (4.5)
Smoking status	48,391		21,768	
Never (%)	17,915	37.0	7,921	36.4
Former (%)	7,248	15.0	8,607	39.5
Current (%)	23,228	48.0	5,240	24.1

667 Values are presented as means (standard deviation) for continuous variables and percentages for others. Age is  
668 from the end of follow-up, and others the last known information during adulthood; BMI, body mass index;  
669 FinnGen data is from FinnGen data release 11.

670 **Figure legends**

671 Figure 1. Study design and cohorts. PGS LST, polygenic score for leisure screentime; CVD,  
672 cardiovascular disease


673

674 Figure 2. Associations between polygenic score for leisure screen time and cardiovascular disease  
675 incidence. Values are hazard ratios (HRs) and 95% confidence intervals (CIs) per one standard  
676 deviation increase in the polygenic score for leisure screen time. We used age as the time scale, and  
677 the first ten principal components of ancestry, sex, and genotyping batch as covariates; CVD,  
678 cardiovascular disease. Incidence values are age-standardized according to the European Standard  
679 Population to enable comparison between FinnGen and HUNT cohorts.


680

681 Figure 3. Cumulative incidence curves for high (> 90<sup>th</sup> percentile [red]) and low (< 10<sup>th</sup> percentile  
682 [blue]) PGS LST groups in the FinnGen cohort based on Cox proportional hazard models and  
683 adjusted for the first ten principal components, sex, and genotyping batch.


Derivation and validation  
of the polygenic score for leisure screen time




Cardiovascular disease	Cases/N	Incidence/10,000 person-years		HR (95% CI)
<b>Any CVD</b>				
FinnGen	168,770/293,250	34.9	■	1.05 (1.05 to 1.06)
HUNT	30,369/35,289	36.5	■	1.05 (1.03 to 1.06)
<b>Hypertensive diseases</b>				
FinnGen	108,040/322,890	20.5	■	1.09 (1.08 to 1.09)
HUNT	14,939/36,331	17.5	■	1.08 (1.06 to 1.09)
<b>Ischemic heart diseases</b>				
FinnGen	64,724/333,012	12.0	■	1.06 (1.05 to 1.07)
HUNT	11,204/36,378	13.6	■	1.07 (1.05 to 1.09)
<b>Cerebrovascular diseases</b>				
FinnGen	34,170/332,730	6.1	■	1.05 (1.04 to 1.06)
HUNT	6,222/36,389	6.3	■	1.04 (1.01 to 1.06)




### Any CVD



### Hypertensive diseases



### Ischemic heart diseases



### Cerebrovascular diseases

